148 related articles for article (PubMed ID: 17419946)
1. Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate.
Rabinovsky R; Uhr JW; Vitetta ES; Yefenof E
Adv Cancer Res; 2007; 97():189-202. PubMed ID: 17419946
[TBL] [Abstract][Full Text] [Related]
2. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state.
Farrar JD; Katz KH; Windsor J; Thrush G; Scheuermann RH; Uhr JW; Street NE
J Immunol; 1999 Mar; 162(5):2842-9. PubMed ID: 10072532
[TBL] [Abstract][Full Text] [Related]
3. Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells.
Marches R; Racila E; Tucker TF; Picker L; Mongini P; Hsueh R; Vitetta ES; Scheuermann RH; Uhr JW
Ther Immunol; 1995 Jun; 2(3):125-36. PubMed ID: 8885131
[TBL] [Abstract][Full Text] [Related]
4. Dormancy in a model of murine B cell lymphoma.
Uhr JW; Marches R
Semin Cancer Biol; 2001 Aug; 11(4):277-83. PubMed ID: 11513563
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
6. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
7. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
8. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
9. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice.
Racila E; Scheuermann RH; Picker LJ; Yefenof E; Tucker T; Chang W; Marches R; Street NE; Vitetta ES; Uhr JW
J Exp Med; 1995 Apr; 181(4):1539-50. PubMed ID: 7535341
[TBL] [Abstract][Full Text] [Related]
10. Cancer dormancy: studies of the murine BCL1 lymphoma.
Uhr JW; Tucker T; May RD; Siu H; Vitetta ES
Cancer Res; 1991 Sep; 51(18 Suppl):5045s-5053s. PubMed ID: 1884380
[TBL] [Abstract][Full Text] [Related]
11. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
12. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
13. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells.
Choi MS; Oh JH; Kim SM; Jung HY; Yoo HS; Lee YM; Moon DC; Han SB; Hong JT
Int J Oncol; 2009 May; 34(5):1221-30. PubMed ID: 19360335
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell dormancy: implications for the biology and treatment of breast cancer.
Fehm T; Mueller V; Marches R; Klein G; Gueckel B; Neubauer H; Solomayer E; Becker S
APMIS; 2008; 116(7-8):742-53. PubMed ID: 18834416
[TBL] [Abstract][Full Text] [Related]
15. Induction of B cell tumor dormancy by anti-idiotypic antibodies.
Yefenof E; Picker LJ; Scheuermann RH; Vitetta ES; Street NE; Tucker TF; Uhr JW
Curr Opin Immunol; 1993 Oct; 5(5):740-4. PubMed ID: 8240736
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
17. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
18. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
[TBL] [Abstract][Full Text] [Related]
19. Mathematical models of cancer dormancy.
Page K; Uhr JW
Leuk Lymphoma; 2005 Mar; 46(3):313-27. PubMed ID: 15621821
[TBL] [Abstract][Full Text] [Related]
20. Tumor dormancy of primary and secondary cancers.
Udagawa T
APMIS; 2008; 116(7-8):615-28. PubMed ID: 18834406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
